Business
Sol-Gel Announces Presentation of Data for its Topical Product Candidates for Acne and Rosacea at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
NESS ZIONA, Israel, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) today announced the presentation
About this update from Sol-gel Technologies Ltd.
[{"type":"text","content":"NESS ZIONA, Israel, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”) today announced the presentation of results from the Company’s Phase 3 trials for its candidates Epsolay® (microencapsulated benzoyl peroxide cream, 5%) for the treatment of moderate-to-severe papulopustular rosacea and Twyneo® (microencapsulated benzoyl peroxide 3% and microencapsulated tretinoin 0.1% cream) for the treatment of moderate-to-severe acne vulgaris. The results of multiple Phase 3 trials as well as a platform technology overview will be highlighted during a poster presentation at the 16th Annual Maui Derm for Dermatologists 2020 Meeting in Grand Wailea, Hawaii available for viewing on January 25th-29th.\n The poster presentations will be available for download from the Events and Presentation page on the Sol-Gel website. Details of the Poster Presentations are as follows: Title: Twyneo® (Microencapsulated Benzoyl Peroxide 3%, Tretinoin 0.1%) Phase 3 Efficacy and Safety: Results from Two Randomized Controlled Clinical Trials Title: Efficacy and Safety of Microencapsulated Benzoyl Peroxide (E-BPO) Cream, 5% in Papulopustular Rosacea: Results from Two Phase 3, Vehicle-Controlled Trials Title: Characterization of Microencapsulated Benzoyl Peroxide (E-BPO) for the Treatment of Papulopustular Rosacea The Twyneo poster debuted and was highlighted at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast, Hawaii running from January 18th-22nd. The Twyneo poster has also been selected for publication in an upcoming edition of SKIN, The Journal of Cutaneous Medicine®, the official journal of the National Society for Cutaneous Medicine. About Papulopustular Rosacea Papulopustular rosacea also known as inflammatory lesion of rosacea, is a chronic and recurrent inflammatory skin disorder that affects nearly 5 million Americans. The condition is common, especially in fair-skinned people of Celtic and northern European heritage. Onset is usually after age 30 and typically begins as flushing and subtle redness on the cheeks, nose, chin or forehead. If left untreated, rosacea can slowly worsen over time. As the condition progresses the redness becomes more persistent, blood vessels become visible and pimples often appear. Other symptoms may include burning, stinging, dry skin, plaques and skin ...